CN Patent

CN108883115A — 用parp抑制剂治疗小细胞肺癌

Assigned to Maddie Wexon Technology Co Ltd · Expires 2018-11-23 · 7y expired

What this patent protects

本文描述了用聚(ADP‑核糖)聚合酶(PARP)抑制剂或其药学上可接受的盐治疗表达Schlafen‑11(SLFN11)的小细胞肺癌受试者的方法。具体地，所述方法包括在来自所述受试者的肿瘤细胞样品中检测SLFN 11，并且向所述受试者施用有效量的PARP抑制剂，诸如talazoparib或talazoparib的甲苯磺酸盐。

USPTO Abstract

本文描述了用聚(ADP‑核糖)聚合酶(PARP)抑制剂或其药学上可接受的盐治疗表达Schlafen‑11(SLFN11)的小细胞肺癌受试者的方法。具体地，所述方法包括在来自所述受试者的肿瘤细胞样品中检测SLFN 11，并且向所述受试者施用有效量的PARP抑制剂，诸如talazoparib或talazoparib的甲苯磺酸盐。

Drugs covered by this patent

Patent Metadata

Patent number
CN108883115A
Jurisdiction
CN
Classification
—
Expires
2018-11-23
Drug substance claim
No
Drug product claim
No
Assignee
Maddie Wexon Technology Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.